NCT05710211 Clonal Architecture of ASXL1-mutated Myelofibrosis
| NCT ID | NCT05710211 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Myelofibrosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-04-24 |
| Primary Completion | 2027-04-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-04-24 with a primary completion date of 2027-04-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Eligibility Criteria
Inclusion Criteria: * Adults (age ≥18 years), * Affiliated to the national social security system, * ASXL1 mutated primary or secondary myelofibrosis, * Signed the consent to participate in the study, * Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * Patient with another active hematological disease or cancer at the time of diagnosis, * Person subject to legal protection scheme or incapable of giving consent.
Contact & Investigator
POUILLART
STUDY DIRECTOR
University Hospital, Angers
Frequently Asked Questions
Who can join the NCT05710211 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05710211 currently recruiting?
Yes, NCT05710211 is actively recruiting participants. Contact the research team at margaux.wiber@chu-angers.fr for enrollment information.
Where is the NCT05710211 trial being conducted?
This trial is being conducted at Angers, France, Brest, France, Cholet, France, Créteil, France and 9 additional locations.
Who is sponsoring the NCT05710211 clinical trial?
NCT05710211 is sponsored by University Hospital, Angers. The principal investigator is POUILLART at University Hospital, Angers. The trial plans to enroll 50 participants.